Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 17
  1. May 19, 2026 · 07:00 · BLCO · Routine +

    Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

    Bausch + Lomb Launches PreserVision AREDS3(TM) Eye Vitamins in the United States

    01
  2. May 19, 2026 · 03:16 · DTC · Routine +

    Defence Therapeutics Bolsters ADC Platform Execution Amidst Capital Market Skepticism

    Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

    02
  3. May 19, 2026 · 03:05 · BNXT · Routine +

    BioNxt Expands GLP-1 Pipeline Amidst MS Platform Progress, Yet Dilution Risks Linger

    BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

    03
  4. May 18, 2026 · 11:20 · XRTX · Routine −

    XORTX closes fire‑sale offering at a 38% discount, shareholders left to weather prolonged cash drought and dilutive pipeline.

    E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering

    04
  5. May 18, 2026 · 03:00 · QNTM · Routine +

    Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

    Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

    05
  6. May 15, 2026 · 20:01 · APPT · Material −

    Founder takes interim CEO role after abrupt exit of public-market shepherd; early-stage credibility in question.

    UberDoc Health Technologies Announces Leadership Transition

    06
  7. May 15, 2026 · 19:40 · MDX · Neutral

    MedX Secures Runway with Debt Refinancing Amidst Dilution Concerns and Modest Cash Injection

    MedX Announces Final Closing of Non-brokered Private Placement

    07
  8. May 15, 2026 · 18:58 · ALGO · Neutral

    Pre-revenue diagnostics firm narrows losses but liquidity runway tightens ahead of commercial launch

    Light AI reports Financial Results for Three Months ended March 31, 2026

    08
  9. May 15, 2026 · 18:00 · ONCO · Neutral

    Onco-Innovations Stock Crashes 98% as Dilution Concerns Outweigh CMC Milestones

    Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

    09
  10. May 15, 2026 · 17:31 · VVTM · Routine −

    Governance Risks Persist Despite Commercial Traction

    VVT Med Provides Update on Management Cease Trade Order

    10
  11. May 15, 2026 · 08:30 · MBIO · Neutral

    MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

    NetworkNews Audio Announces Audio Press Release (APR) Discussing Combining Artificial Intelligence with Speech Analysis to Detect Intoxication

    11
  12. May 15, 2026 · 08:30 · SURE · Routine +

    SureNano Science Ltd.

    NetworkNews Audio Announces Audio Press Release (APR) Discussing Overcoming Limitations on First-Generation GLP-1 Drug Therapies

    12
  13. May 15, 2026 · 07:30 · BCT · Routine +

    BriaCell Diversifies Pipeline with Ovarian Candidate as Phase 3 Breast Cancer Data Looms

    BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+(TM)

    13
  14. May 15, 2026 · 07:00 · MSCL · Routine +

    Satellos Secures Runway to 2027 as Phase 2 DMD Trials Advance, But Burn Rate Accelerates

    Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

    14
← Newer Older →